Please provide your email address to receive an email when new articles are posted on . Dupilumab significantly reduced asthma exacerbations and improved lung function within 2 weeks in children aged ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

Patients with asthma who were with or without a diagnosis of nasal polyps were found to have results with long-term dupilumab. A study published in Annals of Allergy, Asthma & Immunology found that ...

The authors of the retrospective, observational study said it was the first to use electronic medical records to make direct comparisons of these 4 biologics for asthma. A study presented at this year ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Dupilumab for uncontrolled asthma improved mucus ...

NASHVILLE, Tenn. -- Treatment with the biologic dupilumab (Dupixent) was associated with sustained reductions in oral corticosteroid (OCS) use in asthma patients who required both low and high daily ...

Short-term use of oral corticosteroids is associated with an increased risk of sepsis, VTE TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe ...

Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, ...

A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma ...

Asthma diagram, lungs A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes. The ...

In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11. The findings of the ...